PMID- 36249023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Lenvatinib plus transarterial chemoembolization with or without immune checkpoint 
      inhibitors for unresectable hepatocellular carcinoma: A review.
PG  - 980214
LID - 10.3389/fonc.2022.980214 [doi]
LID - 980214
AB  - Lenvatinib plus transarterial chemoembolization (TACE)have become the first 
      choice for patients with hepatocellular carcinoma (HCC) that are unsuitable for 
      TACE. Sorafenib plus TACE therapy for patients with portal vein tumor thrombus 
      (PVTT) achieved positive results. However, Lenvatinib plus TACE appeared to 
      achieve a more advantageous result for these patients based on the phase 3 
      REFLECT trial. Both TACE and lenvatinib therapy have immune-stimulating effects, 
      so would lenvatinib plus TACE and immune checkpoint inhibitors be an advantageous 
      therapy for unresectable HCC (uHCC)? Thirteen articles from PubMed were explored 
      to determine the efficacy and safety of lenvatinib plus TACE with or without PD-1 
      inhibitors therapy. Most of the adverse events (AEs) were manageable. Lenvatinib 
      plus TACE therapy was superior to lenvatinib monotherapy with intermediate stage 
      HCC especially beyond up-to-seven criterion and was superior to TACE monotherapy 
      in patients with uHCC or sorafenib plus TACE therapy in patients with PVTT. 
      Objective response rates (ORRs) of 53.1%-75%, median progression free survival 
      (PFS) of 6.15-11.6 months, and median overall survival (OS) of 14.5-18.97 months 
      were achieved in the lenvatinib plus TACE group. Levatinib plus TACE and PD-1 
      inhibitors achieved ORRs of 46.7% -80.6%, median PFS of 7.3-13.3 months, and 
      median OS of 16.9-24 months. Control studies also confirmed the triple therapy 
      was superior to lenvatinib plus TACE in patients with uHCC. Overall, the triple 
      therapy is a promising treatment for patients with uHCC, including main PVTT and 
      extrahepatic metastasis. Lenvatinib plus TACE therapy was also preferable for 
      intermediate stage HCC beyond up-to-seven criterion and for patients with PVTT.
CI  - Copyright (c) 2022 Sun, Xu, Meng, Liu, Wang, Li, Li and Chen.
FAU - Sun, Liwei
AU  - Sun L
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
AD  - Graduate school, Shandong First Medical University & Shandong Academy of Medical 
      Sciences, Jinan, China.
FAU - Xu, Xuelong
AU  - Xu X
AD  - Zibo Maternal and Child Health Care Hospital, Zibo, China.
FAU - Meng, Fanguang
AU  - Meng F
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
AD  - Graduate school, Shandong First Medical University & Shandong Academy of Medical 
      Sciences, Jinan, China.
FAU - Liu, Qian
AU  - Liu Q
AD  - Department of Radiology, The Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Zhejiang, China.
FAU - Wang, Hankang
AU  - Wang H
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
AD  - Graduate school, Shandong First Medical University & Shandong Academy of Medical 
      Sciences, Jinan, China.
FAU - Li, Xiaodong
AU  - Li X
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
AD  - Graduate school, Shandong First Medical University & Shandong Academy of Medical 
      Sciences, Jinan, China.
FAU - Li, Guijie
AU  - Li G
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Radiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and 
      Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220928
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9555078
OTO - NOTNLM
OT  - immune checkpoint inhibitors
OT  - immune checkpoint programmed death factor 1 inhibitors
OT  - lenvatinib
OT  - transarterial chemoembolization
OT  - unresectable hepatocellular carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/01/01
CRDT- 2022/10/17 05:17
PHST- 2022/06/28 00:00 [received]
PHST- 2022/09/05 00:00 [accepted]
PHST- 2022/10/17 05:17 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.980214 [doi]
PST - epublish
SO  - Front Oncol. 2022 Sep 28;12:980214. doi: 10.3389/fonc.2022.980214. eCollection 
      2022.